PDF(Pubmed)
Abstract：
This editorial comments on the study by Ma et al, which delves into the efficacy and predictive factors associated with the combination of transarterial chemoembolization, lenvatinib, and programmed cell death protein-1 inhibition for the management of unresectable hepatocellular carcinoma. Analysing data from a retrospective study involving 102 patients, the treatment showcased a median overall survival (OS) of 26.43 months and a median progression-free survival (PFS) of 10.07 months. Notably, the objective response rate and disease control rate reached 61.76% and 81.37%, respectively. Specific factors such as Barcelona Clinic Liver Cancer (BCLC) Classification B-stage, early neutrophil-to-lymphocyte ratio response, and early alpha-fetoprotein response (> 20% decrease) correlated with superior OS and PFS. The triple therapy exhibited promising efficacy, particularly in BCLC B-stage disease, with prognostic markers aiding in patient stratification. Acknowledging the retrospective nature of the study design, future research should address this limitation and incorporate longer follow-up periods for a comprehensive evaluation of long-term outcomes.
摘要：
这篇社论评论了马等人的研究，其中探讨了与经动脉化疗栓塞联合相关的疗效和预测因素，lenvatinib,和程序性细胞死亡蛋白-1抑制治疗不可切除的肝细胞癌。分析一项涉及102名患者的回顾性研究的数据，该治疗的中位总生存期(OS)为26.43个月,中位无进展生存期(PFS)为10.07个月.值得注意的是,客观有效率和疾病控制率分别达到61.76%和81.37%,分别。具体因素，如巴塞罗那临床肝癌（BCLC）分类B期，早期中性粒细胞与淋巴细胞比值反应，早期甲胎蛋白反应(>20%下降)与优越的OS和PFS相关。三联疗法显示出有希望的疗效，特别是在BCLCB期疾病中，预后标志物有助于患者分层。承认研究设计的回顾性性质，未来的研究应解决这一局限性,并纳入更长的随访期,以全面评估长期结局.
